Connect with us

Requirement for Buprenorphine Data Waiver is Eliminated

Posted over 1 year ago

On December 29, 2022, with the signing of the Consolidated Appropriations Act of 2023 (the Act), Congress eliminated the “DATA-Waiver Program.”
The elimination of the X-Waiver will increase access to buprenorphine for those in need.
All DEA registrants should be aware of the following:
A DATA-Waiver registration is no longer required to treat patients with buprenorphine for opioid use disorder.
Going forward, all prescriptions for buprenorphine only require a standard DEA registration number. The previously used DATA-Waiver registration numbers are no longer needed for any prescription.
There are no longer any limits or patient caps on the number of patients a prescriber may treat for opioid use disorder with buprenorphine.
The Act does not impact existing state laws or regulations that may be applicable.
Separately, the Act also introduced new training requirements for all prescribers. These requirements will not go into effect until June 21, 2023.


Only active members can comment on this announcement.

Learn more about membership